Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Czech National Bank
Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...
FiercePharma11d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
The company is also testing tirzepatide in heart failure ... said in the report. “Now with Zepbound, the revolution ...
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.
Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
While Eli Lilly and Company ( NYSE:LLY ) shareholders are probably generally happy, the stock hasn't had particularly... The U.S. Food and Drug Administration (FDA) recently approved Zepbound ...
Eli Lilly and Company: Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Ka inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...